NCT01775280

Response of Hepatic Tumors to Radioembolization

Radiologic, Histologic and Immunologic Response to Radioembolization of Hepatic Tumors

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Zurich · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study enrolls patients with non-resectable or borderline resectable hepatocellular carcinoma (HCC), intraheaptic choalngiocarcinoma (IHCC) or colorectal cancer metastasis. Patients are not a candidates for liver transplantation and have only limited extrahepatic disease. All patients are treated with radioembolization. Primary endpoint is the percentage of patients that can be downstaged to resectability. Secondary endpoints are radiologic response to radioembolization,tissue response to radiomembolization and systemic immune response and intra-tumoral T-cell response to radioembolization. * Trial with radiotherapy

Conditions

• Hepatocellular Carcinoma
• Intrahepatic Cholangiocarcinoma
• Liver Metastasis

Interventions

Type	Name	Description
RADIATION	Injection of Ytttrium-90 microspheres into the hepatic artery	INjection of Y-90 particles into the hepatic artery using endovascular access

Timeline

• Start date: 2012-10-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2013-01-24
• Last updated: 2015-06-09

Locations

1 site across 1 country: Switzerland